Clinical Trial Update: Rivet PVS Therapy in Group 2 PH-HFpEF Canada [NA]

View source ↗

Summary

The Rivet PVS Therapy trial in Group 2 pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF) in Canada has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Pulmonary Hypertension

Drugs mentioned

• Rivet PVS Therapy

Snippet

Sponsor: NXT Biomedical | Conditions: Heart Failure, Pulmonary Hypertension | NA | Status: WITHDRAWN